GENFIT hires Thomas Baetz as Chief Financial Officer and adds two new members to its Executive Committee

Lille, France; Cambridge, MA; April 22, 2021 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with metabolic and liver diseases, today announced that Thomas Baetz has been appointed as Chief Financial Officer. Thomas Baetz joins the Executive Committee, along with Stefanie Magner, Chief Compliance Officer.

Thomas Baetz has 18 years of extensive global experience in corporate finance and investment, acquired in both start-ups and publicly listed companies specialized in healthcare and technology, including two years in the United-States and seven years in China. Prior to joining GENFIT, he was Director of Healthcare at Dragon Financial Partners, where he advised European healthtech companies on licensing agreements, fundraising and operational management. Previously, he spent four years as CFO and Head of Asia-Pacific at the innovative medtech Impeto Medical in Paris and Hong-Kong, collaborating closely with the founders on the definition and implementation of their corporate strategy. He held leadership positions in finance at Cegedim for 10 years, managing the financial control and leading the financial integration during its acquisition of Dendrite. As Senior VP Corporate Development, he oversaw acquisitions, company creations and asset sales, and played an instrumental role, among other financing activities, in completing a capital increase backed by the Fonds Stratégique d’Investissement (Bpifrance). He began his career in banking and strategy consulting.

Thomas graduated from ESCP Europe and earned a MSc. in Finance and Actuarial Science from the École Nationale Supérieure de la Statistique et de l’Administration Économique (ENSAE).

Thomas Baetz, CFO of GENFIT commented: “I am pleased to join GENFIT at a time when the Company is executing on a strategic rebound focused on its two major programs. The renegotiation of the convertible debt finalized in January and the cost-control plan initiated last year place GENFIT in a situation where it can build its future on strong foundations, and with clear financial visibility. I am eager to pursue the work that has already been started.”